Biopharmaceutical company Sosei Group Corporation (TSE:4565) said on Wednesday that it plans to introduce the ORAVI Mucoadhesive Tablets in 50mg in Japan for the treatment of oropharyngeal candidiasis (OPC).

On 4 February 2019, the launch will be initiated by the company's wholly-owned Japanese subsidiary Sosei Co Ltd (the Business).

In conjunction, Sosei Co Ltd has awarded an exclusive license to FUJIFILM Toyama Chemical Co Ltd for the commercialisation of ORAVI in Japan. The Business is entitled to receive royalties on sales in Japan from FUJIFILM Toyama Chemical, plus additional payments based on the achievement of further sales-based milestones.

ORAVI is a novel once-daily mucoadhesive tablet formulation of the antifungal agent miconazole for the treatment of oropharyngeal candidiasis (OPC), a condition that occurs frequently in immunocompromised patients due to HIV, malignant tumours, etc. ORAVI has been designed to deliver a sustained therapeutic concentration of miconazole directly in the mouth. Oropharyngeal candidiasis is a fungal infection caused mainly by Candida albicans, added the company.

Additionally, ORAVI was first approved in 2006 in France and is currently marketed in two European countries and the US under the trade names Loramyc/Oravig.